Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 2/3 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 149pembrolizumab 131Cyclophosphamide 118Magnetic Resonance Spectroscopy 117Biopsy 105fludarabine 89Nivolumab 62Carboplatin 54Cisplatin 49Gemcitabine 48Radiotherapy 47venetoclax 45Paclitaxel 43Cetuximab 40fludarabine phosphate 39Ipilimumab 37Fluorouracil 36atezolizumab 33Bevacizumab 33durvalumab 31Oxaliplatin 29X-Rays 28Leucovorin 28Dexamethasone 28Radiation 27Irinotecan 27Cytarabine 26Azacitidine 26Injections 24Radiosurgery 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × futibatinib × 90 days × Clear all
NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡